Dr. Douglas Dieterich: “FDA Warns of Cardiac Effect When Heart Drug Mixed With Hepatitis C Meds”
A potentially life-threatening slowing of the heart can occur when the common heart drug amiodarone is taken with new hepatitis C medications, the U.S. Food and Drug Administration warns. The dangerous slowing of the heart -- called symptomatic bradycardia -- can occur when amiodarone is taken with the hepatitis C drugs Harvoni (ledipasvir/sofosbuvir) or Sovaldi (sofosbuvir) and combined with another direct-acting antiviral for the treatment of hepatitis C. "While this is a potentially devastating drug interaction in real life, it is unlikely to be a major issue," said Dr. Douglas Dieterich, a professor of liver diseases at the Icahn School of Medicine at Mount Sinai in New York City. "In fact, I cannot recall treating a hepatitis C patient who was on amiodarone in the last five years," he said. Learn more
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
